FDA Publicly Identifying Companies Who May Be Delaying Generics


List posted last week on FDA website

The U.S. Food and Drug Administration (FDA) has followed through on its promise to publicly name companies it says may be gaming drug laws to block generic competition.

The unprecedented move is part of the Trump administration’s effort to bring down the prices of pharmaceuticals. The list was posted on the FDA’s website last Thursday, and includes dozens of companies—both generic and brand-name organizations represented—the agency said appear to have refused to give up samples of their product to generic companies seeking to make copies.

Commissioner Scott Gottlieb, MD, said the agency has received over 150 pleas for help from generic drugmakers who have been unable to get samples from companies.

“We’re also notifying the Federal Trade Commission (FTC) — the agency responsible for addressing anticompetitive business practices — about these inquiries,” he said.

The complete FDA list is available on the organization’s website.

SOURCE: Medscape


156 words

About Author

Rob Senior
Rob Senior

Rob has 15 years of experience writing and editing for healthcare. He previously worked for ADVANCE from 2002 to 2012.

Leave A Reply

Log in or register to comment on this article.